痛泻宁颗粒联合培菲康治疗感染后肠易激综合征的临床研究  

The effect of Tongxiening Keli combined with Birid Triple Viable in treatment of post-infectious irritable bowel syndrome

作　　者：梁海清[1] 王世和[1] 

机构地区：[1]山东省德州市人民医院内二科,253014

出　　处：《重庆医学》2013年第32期3898-3899,共2页Chongqing medicine

摘　　要：目的研究痛泻宁颗粒联合培菲康治疗感染后肠易激综合征的有效性。方法将112例腹泻型感染后肠易激综合征患者分为2组,治疗组60例(予痛泻宁颗粒联合培菲康治疗),对照组52例(单用培菲康治疗),治疗7周后对比疗效。结果治疗组的肠道症状评分明显低于对照组(P<0.05);治疗组总有效率91.7%,对照组65.4%,治疗组疗效明显优于对照组(P<0.01)。结论痛泻宁颗粒联合培菲康治疗腹泻型感染后肠易激综合征是有效的临床用药方案。Objective To study the effect of Tongxiening Keli in combination with Birid Triple Viable（BIFICO） in treatment of post-infectious irritable bowel syndrome（PI-IBS）. Methods 112 cases of diarrhea predominant PI-IBS were divided into combina- tion treatment group（n= 60） and control group（n= 52）. Combination treatment group received both Tongxiening Keli and BIFICO treatment,while the control group received BIFICO treatment only. After 6-week treatment, the therapeutic effect were compared between the two groups. Results The intestinal symptoms grading of combination treatment group was significantly lower than that of control group（P〈0.05） ;The total effective rate of combination treatment group was 91.7% ,the total effective rate of con- trol group was 65.4 %, curative effect in combination treatment group was superior to the control group （P〈0.01）. Conclusion Tongxiening Keli combined with BIFICO is evident effective in treatment of diarrhea-predominant PI-IBS.

关 键 词：肠易激综合征 临床用药 研究 痛泻宁颗粒 

分 类 号：R574.6[医药卫生—消化系统]